Why this story matters: While it may not dominate the 24-hour news cycle, the development highlighted in this article represents a significant shift toward a better future, proving that constructive action is consistently gaining ground behind the scenes.
Quick summary: This story highlights recent developments related to study, showing how constructive action can lead to meaningful results.
Five years ago, a group of patients with clinical depression participated in a therapy trial for psilocybin, the psychedelic substance produced by over 200 species of mushrooms.
The study, published by the Journal of the American Medical Association, involved two participant groups, with one receiving treatment immediately and the other receiving it after a short waiting period. Ultimately, both groups took two doses of psilocybin alongside 13 hours of psychotherapy.
In 2025, the majority of participants did a follow-up study, and the results were overwhelmingly positive: Two-thirds of trial participants were in “complete remission” from depression.
Would you like to read more good news about Study, Mushrooms, Psychedelic, Symptomfree, Taking, and Depression?
“We found that 67% were in remission at five years, compared to 58% at one year,” the study’s lead author, Professor Alan Davis, told Ohio State News.
Davis, who serves as the director at The Ohio State University’s Center for Psychedelic Drug Research and Education, also said that the majority of patients also saw reduced anxiety and improved well-being “across the board.”
There was good news even for patients who weren’t entirely “symptom-free.” Select patients struggling with “debilitating” depression reported that their depression felt “more situational and manageable” — even years later.
A version of this article originally appeared in the 2026 Mental Health Edition of the Goodnewspaper.
Header image via PickPik
GoodHeadlines.org curates positive and solution-focused stories from trusted sources around the world.
